Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression

Shadab Kazmi(Cancer Research Center), Haval Shirwan(Cancer Research Center)
JCI Insight
March 17, 2026
Cited by 0


Related Papers